Application of ITF2357 in preparation of medicine for preventing and treating coronavirus

A technology of ITF2357, 1.ITF2357, used in antiviral agents, drug combinations, pharmaceutical formulations, etc., can solve problems such as poor efficacy, and achieve the effects of low effective concentration, increased effect, and high therapeutic index

Pending Publication Date: 2022-05-06
SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the current treatment methods are symptomatic treatment, especially for some severe patients with poor curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ITF2357 in preparation of medicine for preventing and treating coronavirus
  • Application of ITF2357 in preparation of medicine for preventing and treating coronavirus
  • Application of ITF2357 in preparation of medicine for preventing and treating coronavirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Construction, Production and Verification of Pseudovirus Particles Modified by New Coronavirus S Protein

[0036] In order to simulate the natural process of SARS-CoV-2 using the S protein to recognize the ACE2 receptor to infect host cells, a pseudovirus with a replication-deficient lentivirus as the core and modified with the SARS-2-S protein was constructed particles.

[0037] The construction method adopts the article Xiuyuan Ou et al. (published on March 27, 2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature communications, 11(1), 1 -12. Published method.

[0038] First, the DNA sequence of the SARS-2-S protein was modified without changing its amino acid sequence by means of codon optimization, which facilitated the massive expression of SARS-2-S in 293T cells ( figure 1 A). Subsequently, using the replication-deficient HIV lentivirus commonly used in the laboratory as the c...

Embodiment 2

[0040] Example 2 Cell Biology Platform Screening Clinical Drugs to Inhibit SARS-2-S Pseudovirus Particle Infection

[0041] Utilize the SARS-2-S pseudovirion in vitro infection model (Luciferase reporter system and immunofluorescence staining localization system) constructed in Example 1 to carry out ITF2357 in vitro cell biology verification. ACE2-GFP stably transfected 293T cells were inoculated in 96-well plates, and the cells were pretreated with different concentrations of ITF2357 drugs for 2 hours, and then added with SARS-2-S pseudovirion particles to infect for 3 hours, and then the supernatant was removed and replaced with fresh complete medium. After 40 hours of infection, the cells were lysed using the Luciferase Assay System (Promega) and the reaction substrate was added. Glomax 96 was used to measure the luciferase luminescence intensity, which is proportional to the infection efficiency of virus particles.

[0042] The results of Luciferase activity detection sho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of ITF2357 in preparation of a medicine for preventing and treating coronavirus. Specifically, the invention discloses application of ITF2357 or a pharmaceutically acceptable salt, an isotope, a stereoisomer, a mixture of stereoisomers, a tautomer, an ester, an amide or a prodrug thereof in preparation of drugs for prevention and treatment of diseases caused by coronavirus. The coronavirus is a novel coronavirus SARS-Cov-2, a novel coronavirus SARS-CoV, a novel coronavirus HCoV 229E, a novel coronavirus NL63, a novel coronavirus OC43, a novel coronavirus HKU1 and a novel coronavirus MERS-CoV. The diseases caused by the coronavirus are pneumonia or complications of the pneumonia caused by any one of SARS-Cov-2 virus, SARS-CoV virus, HCoV 229E virus, NL63 virus, OC43 virus, HKU1 virus or MERS-CoV virus. The invention proves that ITF2357 has a novel coronavirus inhibiting effect on new coronal pneumonia for the first time, is low in half effective concentration and has great potential.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of ITF2357 in the preparation of medicines for preventing and treating coronavirus. Background technique [0002] Novel coronavirus pneumonia (Corona Virus Disease 2019) is an infectious disease caused by a new type of coronavirus (SARS-Cov-2) infecting the human body. , 2020, 395(10223):507-513; The Lancet, 2020, 395(10223):497-506]. Coronaviruses belong to the genus Coronavirus in the family Coronaviridae. Viruses of the genus Coronavirus are positive-strand single-stranded RNA viruses with an envelope (envelope), with a diameter of about 80-120nm. Its genetic material is the largest among all RNA viruses, and generally only infects humans, mice, pigs, cats, and dogs. , Avian vertebrates. Coronaviruses were first isolated from chickens in 1937. The shape of coronavirus particles is irregular, with a diameter of about 60-220nm. The virus has an envelope s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/27A61K45/06A61P31/14A61P11/00
CPCA61K31/27A61K45/06A61P31/14A61P11/00A61K2300/00
Inventor 袁曙光李红昌邹荣峰崔文强刘科李红春陈显翀
Owner SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap